ArticleMedical mycology2025
Impact of glycemic control on coccidioidomycosis outcomes in patients with underlying diabetes mellitus in central California.
Article in Medical mycology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Contribution of fungal diseases to the U.S. chronic disease burden.Clinical microbiology reviews · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes mellitus (DM) is a known risk factor for severe coccidioidomycosis. Central California has some of the highest rates of DM in the USA, according to CDC data. This study examines the impact of glycemic control on the severity and outcomes of coccidioidomycosis in this high-DM-prevalent region. A retrospective analysis was conducted on patients with both coccidioidomycosis and DM from 2014 to 2022 at a large referral center in Fresno, California. Data collected included demographics, presentation, HbA1c levels, management, and outcomes. Fisher's exact test and the Wilcoxon-Rank sum test were used to analyze categorical and continuous measures, respectively. Logistic regression was applied for binary outcomes. We analyzed 131 patients with coccidioidomycosis and DM (62% male and 64% Hispanic). The median HbA1c at the diagnosis of coccidioidomycosis was 9%. A total of 64% developed complicated pulmonary disease, and 56% cavitary pulmonary disease. Higher HbA1c at diagnosis was associated with increased odds of complicated pulmonary disease (OR = 1.40; 95% CI: 1.05, 1.85), cavitary disease (OR = 1.43; 95% CI: 1.09, 1.88), and decreased odds of resolution (OR = 0.66; 95% CI: 0.48, 0.93). Central California, with one of the highest burdens of coccidioidomycosis, also has an increased prevalence of DM. Our study population had significantly uncontrolled DM. We also found that the level of glycemic control impacted the severity of pulmonary coccidioidomycosis and rates of resolution. Achieving reasonable glycemic control and addressing barriers to effective DM management may be just as crucial as effective antifungal therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.